Could an MS drug fix a key brain chemical in schizophrenia?

NCT ID NCT06957808

First seen Feb 17, 2026 · Last updated Apr 28, 2026 · Updated 10 times

Summary

This study looks at whether diroximel fumarate, a drug already used for multiple sclerosis, can increase a natural antioxidant called glutathione in the brains of people with schizophrenia. Thirty adults with stable schizophrenia will take the drug for two weeks, then either continue it or switch to a placebo for another two weeks. Researchers will use brain scans and electrical recordings to measure changes in brain chemistry, activity, and symptoms. The goal is to understand if boosting glutathione could be a new treatment target for schizophrenia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Department of Computer Science, Faculty of Engineering Science, University College London

    RECRUITING

    London, Greater London, WC1E 6BT, United Kingdom

    Contact Email: •••••@•••••

    Contact

  • School of Psychology, University of birmingham

    RECRUITING

    Birmingham, B15 2TT, United Kingdom

    Contact Email: •••••@•••••

    Contact

  • South London and Maudsley NHS Foundation Trust

    RECRUITING

    London, Greater London, SE58AZ, United Kingdom

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.